『Can Ozempic & GLP-1s Make You Blind? A Doctor Explains』のカバーアート

Can Ozempic & GLP-1s Make You Blind? A Doctor Explains

Can Ozempic & GLP-1s Make You Blind? A Doctor Explains

無料で聴く

ポッドキャストの詳細を見る

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
#Ozempic #GLP1 #Wegovy #EyeHealth #obesitymedicine Can Ozempic, Wegovy or Mounjaro make you blind? A viewer asked me this, and it deserves an honest, evidence-based answer. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist.In this video I review every major study on GLP-1 medications and NAION, a rare "stroke" of the optic nerve:The Mass Eye and Ear study that sparked the headlinesThe larger studies from Denmark, Norway and the USThe randomized trialsI also cover what the European Medicines Agency, the UK's MHRA and the American Academy of Ophthalmology concluded, plus the separate issue of diabetic retinopathy. You'll learn the real risk in actual numbers, who is at higher risk, and a 5-step eye-safety plan, including the one warning sign that means you go to the ER the same day.TIMESTAMPS0:00 Can GLP-1s make you blind? A viewer's question0:58 Who I am and why this matters1:37 What is NAION? The "stroke" of the optic nerve3:15 How the alarm started: the Mass Eye and Ear study4:16 What the bigger studies found6:13 GLP-1 Masterclass6:51 What regulators and eye specialists concluded8:44 Putting the risk in perspective9:28 The other eye issue: diabetic retinopathy10:41 Free GLP-1 Diet Cookbook11:01 Who is at higher risk?12:16 The 5-step eye-safety plan14:10 What to watch next📩 FREE GLP-1 Diet Cookbook + Weekly Newsletterhttps://www.drmohammedpaika.com/newsletter🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.comREFERENCESStatPearls: Nonarteritic anterior ischemic optic neuropathy. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK559045/Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 1994;14(1):38-44Hathaway JT, Shah M, Hathaway DB, et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739Grauslund J, Abou Taha A, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of NAION in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of NAION: a Danish–Norwegian cohort study. Diabetes Obes Metab. 2025;27(6):3094-3103Hsu AY, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025. doi:10.1001/jamaophthalmol.2025.0349Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327DeParis SW, et al. GLP-1 receptor agonists and the risk of NAION: a consensus statement by NANOS and the American Academy of Ophthalmology. Ophthalmology. 2026;133(8)NAION risk with semaglutide: what we know so far (includes Chou et al., 18,657 patients). Eye. 2025. https://www.nature.com/articles/s41433-025-03833-yLiu Z, Raveendran D, Fourlanos S, et al. Rate and risk of NAION with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis. Ophthalmology. 2026;133:589-598European Medicines Agency (PRAC). NAION a very rare side effect of semaglutide. June 2025. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovyMHRA Drug Safety Update: Semaglutide and risk of NAION. Feb 5, 2026Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232Centers for Disease Control and Prevention. Diabetes and vision lossMarso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844Vilsbøll T, et al. Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897Leinung M, Patel N, Bettadahalli S, Paika MK, et al. Benefits of short-term professional continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013Campbell UB, et al. Acute NAION and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139-151⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません